Quince Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a QNCX research report →
About the company
Quince Therapeutics, Inc. (QNCX) operates as a biopharmaceutical firm dedicated to developing targeted treatments for debilitating and rare diseases. A cornerstone of their innovation is an extensive bone-targeting drug delivery platform, engineered to accurately transport diverse therapeutic agents, such as small molecules, peptides, and large molecules, directly to affected bone areas like fractures and disease sites.
- CEO
- Dirk Thye
- IPO
- 2019
- Employees
- 36
- HQ
- South San Francisco, CA, US
Price Chart
- Market Cap
- $4.80M
- P/E
- -0.14
- P/S
- 0.00
- P/B
- 0.28
- EV/EBITDA
- 1.01
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 1823.49%
- ROIC
- -280.90%
- Revenue
- $0 · 0.00%
- Net Income
- $-83,979,000 · -47.78%
- EPS
- $-336.00 · -28.24%
- Op Income
- $-50,429,000
- FCF YoY
- -29.90%
- 52W High
- $910.00
- 52W Low
- $15.10
- 50D MA
- $21.92
- 200D MA
- $247.31
- Beta
- 1.37
- Avg Volume
- 231.83K
Get TickerSpark's AI analysis on QNCX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 11, 26 | Lamond David | other | 2,700 |
| Jun 11, 26 | Senner Christopher J. | other | 2,700 |
| May 18, 26 | Roberts Brigette | other | 6,837,319 |
| May 18, 26 | Roberts Brigette | other | 2,070,107 |
| May 18, 26 | Roberts Brigette | other | 362,092 |
| May 18, 26 | Roberts Brigette | other | 228,855 |
| May 18, 26 | Roberts Brigette | other | 133,615 |
| May 18, 26 | Roberts Brigette | other | 124,830 |
| May 18, 26 | Roberts Brigette | other | 69,350 |
| May 18, 26 | Roberts Brigette | other | 34,675 |
Our QNCX coverage
Recent articles, reports, and earnings notes.
No research on QNCX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate QNCX report →Similar companies
Peers in the same neighborhood.